大腸がん治療薬の世界市場（2021年～2028年）

世界の大腸がん治療薬市場の成長は、大腸がんの発生率の増加、ライフスタイルの変化、高齢人口の増加、認知度の向上、大腸がんに対するケアを充実させるための政府の政策などが要因となっています。ただし、従来の化学薬品に対する生物製剤や標的治療薬の優位性は、同市場の成長をにマイナスの影響を与えるおそれがあります。

当レポートは、世界の大腸がん治療薬市場について調査しており、市場規模、機会や影響、成長および抑制要因、COVID-19による影響、タイプ・治療・流通チャネル・地域別の市場分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 世界の大腸がん治療薬市場の調査手法と範囲

• 調査手法
• 調査の目的と調査範囲

第2章 世界の大腸がん治療薬市場-市場の定義と概要

第3章 世界の大腸がん治療薬市場-エグゼクティブサマリー

• タイプ別の市場内訳
• 治療別の市場内訳
• 流通チャネル別の市場内訳
• 地域別の市場内訳

第4章 世界の大腸がん治療薬市場-市場力学

• 市場に影響を与える要因
  • 成長要因
  • 抑制要因
  • 市場機会
  • 影響分析

第5章 世界の大腸がん治療薬市場-業界分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• 償還分析
• アンメットニーズ

第6章 世界の大腸がん治療薬市場-COVID-19分析

• 市場でのCOVID-19の分析
  • COVID-19以前の市場シナリオ
  • 現在の市場シナリオ
  • COVID-19以後または今後のシナリオ
• COVID-19における価格動向
• 需要と供給のスペクトル
• パンデミック時の市場に関連する政府のイニシアチブ
• メーカーの戦略的イニシアチブ
• 結論

第7章 世界の大腸がん治療薬市場-タイプ別

• イントロダクション
• 市場規模分析および前年比成長分析
• 市場魅力指数
  • プログラム細胞死タンパク質1/PD1リガンド1（PD1/PDL1）阻害剤
  • チロシンキナーゼ（TKI）阻害剤
  • 免疫調節剤
  • BRAFまたはMEK阻害剤

第8章 世界の大腸がん治療薬市場-治療別

• イントロダクション
• 市場規模分析および前年比成長分析
• 市場魅力指数
  • 免疫療法
  • 標的療法
  • 化学療法

第9章 世界の大腸がん治療薬市場-流通チャネル別

• イントロダクション
• 市場規模分析および前年比成長分析
• 市場魅力指数
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • その他

第10章 世界の大腸がん治療薬市場-地域別

• イントロダクション
• 市場規模分析および前年比成長分析
• 市場魅力指数
• 北米
  • イントロダクション
  • 主要地域別の力学
  • タイプ別：市場規模分析、および前年比成長分析
  • 治療別：市場規模分析、および前年比成長分析
  • 流通チャネル別：市場規模分析、および前年比成長分析
  • 国別：市場規模分析、および前年比成長分析
• 欧州
  • イントロダクション
  • 主要地域別の力学
  • タイプ別：市場規模分析、および前年比成長分析
  • 治療別：市場規模分析、および前年比成長分析
  • 流通チャネル別：市場規模分析、および前年比成長分析
  • 国別：市場規模分析、および前年比成長分析
• 南米
  • イントロダクション
  • 主要地域別の力学
  • タイプ別：市場規模分析、および前年比成長分析
  • 治療別：市場規模分析、および前年比成長分析
  • 流通チャネル別：市場規模分析、および前年比成長分析
  • 国別：市場規模分析、および前年比成長分析
• アジア太平洋
  • イントロダクション
  • 主要地域別の力学
  • タイプ別：市場規模分析、および前年比成長分析
  • 治療別：市場規模分析、および前年比成長分析
  • 流通チャネル別：市場規模分析、および前年比成長分析
  • 国別：市場規模分析、および前年比成長分析
• 中東とアフリカ
  • イントロダクション
  • 主要地域別の力学
  • タイプ別：市場規模分析、および前年比成長分析
  • 治療別：市場規模分析、および前年比成長分析
  • 流通チャネル別：市場規模分析、および前年比成長分析
  • 国別：市場規模分析、および前年比成長分析

第11章 世界の大腸がん治療薬市場-企業プロファイル

• Roche
  • 企業概要
  • 製品ポートフォリオ・概要
  • 要点
  • 財務概要
• Eli Lilly and Company
• Pfizer
• Abbott Laboratories
• Sanofi S.A
• Bristol-Myers Squibb
• Amgen
• Genentech
• Merck & Co
• Teva Pharmaceuticals

第12章 世界の大腸がん治療薬市場-DataM

• 付録
• 当社・サービスについて
• お問い合わせ

Market Overview

The Global Colorectal Cancer Drugs Market size was worth US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Colon cancer is also called colorectal cancer, is a term that combines colon cancer and rectal cancer, which begins in the rectum. Colon cancer is a type of cancer that starts in the large intestine (colon), is the final part of the digestive tract. It mainly affects older adults, though it can happen at any age, usually begins as tiny, non-cancerous (benign) clumps of cells called polyps that form inside the colon. As time passes, some of these polyps can become colon cancers. They may be small and produce few if any, symptoms. Usually, doctors recommend regular screening tests to prevent colon cancer by identifying and removing polyps before they turn into cancer. Signs and symptoms associated with colorectal cancer are weight loss, fatigue, weakness, abdominal discomfort, pain, cramps, persistent change in bowel habits, diarrhea and constipation, rectal bleeding, and blood in the stools and others.

Many treatments are available to control it if colon cancer develops, including surgery, radiation therapy, and drug treatments, such as chemotherapy, targeted therapy, and immunotherapy.

Market Dynamics

The global Colorectal Cancer Drug market growth is driven by the growing incidence of Colorectal cancers, and changing lifestyle, increasing geriatric population, increasing awareness, government policies to provide better care for colorectal cancer.

Increasing incidence of Colorectal Cancers, is expected to drive the global Colorectal Cancer Drug market during the forecast period.

The number of colorectal cancer cases worldwide has been increasing. As per the American Cancer Society (ACS) estimates, there will be around 101,420 new colon cancer cases, and around 44,180 new cases of rectal cancer are registered in the USA in 2019. The diagnosed incident colorectal cancer cases are expected to increase by 27.3% to 672,400 cases by 2037. This increase can be attributed to a low-fiber diet, obesity, alcohol and tobacco consumption, amongst others. The increase in the number of colorectal cases will add to the overall global colorectal cancer drug market.

Increased Awareness and Effective Product Launches is expected to drive the global Colorectal Cancer Drug market during the forecast period.

Increased awareness about colorectal cancer and rise in product launch driving the global colorectal drug market rapidly.

Many market key leaders have introduced several advanced medicines for effective colorectal cancer treatment. For instance, In July 2019, Amgen and Allergan launched Mvasi and Kanjinti, the first Anticancer Biosimilars in the US used to treat colorectal cancer.

Increased usage of biologics and targeted therapies is likely to hamper the global colorectal cancer drugs market.

Increased usage of biologics and targeted therapies is likely to hamper the market growth. Biologic therapy helps the body's immune system fight against cancer rather than chemical drugs, which reduces the body's immune power. Targeted therapies block the growth and spreading of colorectal cancer even in stage IV, where chemical drugs are ineffective. For instance, the FDA has approved some targeted therapies to treat colorectal cancer, including bevacizumab, cetuximab, and panitumumab. The advantages of biologics drugs and targeted therapies over conventional chemical drugs might negatively influence the market.

COVID-19 Impact Analysis

Due to the covid-19 pandemic outbreak, the market for Global Colorectal Cancer drugs market was seen to be down, due to the barriers in production and sales segments. Since the outbreak led to the shutdown of all manufacturing firms except for masks, sanitizers and ventilators. Hence, the Drugs were manufactured less compared to previous years, during the outbreak.

Segment Analysis

Based on the Type, the global Colorectal cancer drugs market is segmented into Vascular endothelial growth factor inhibitors (VEGF), Epidermal growth factor receptor (EGFR) inhibitors, Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors, BRAF or MEK Inhibitors, Tyrosine Kinase (TKI) Inhibitors, Immunomodulators.

Vascular endothelial growth factor inhibitors are expected have largest share. The Vascular endothelial growth factor (VEGF)/ vascular endothelial growth factor receptor (VEGFR) inhibitors are the agents that inhibit VEGF and VEGFR. VEGR and VEGFR (a tyrosine kinase receptor) signaling modulate angiogenesis, making new blood vessels from existing blood vessels. They are used to treat various types of cancers. The drugs included in this type Avastin, Eylea, cometriq. The Avastin segment, picked up $7.12 billion of global annual sales by 2019. For instance,

Disease - Colorectal Cancer

• Treatment/ Intervention - Drug: 5-FU based doublet chemotherapy, Drug: bevacizumab

• Phase - Phase 4

• Sponsor - Hoffmann-La Roche

Based on the Therapy Type, the global Colorectal Cancer Drugs market is segmented into Immunotherapy, Target therapy, Chemotherapy.

Immunotherapy is used to fight cancer cells by taking advantage of the human immune system. There are several immunotherapy drugs available for colorectal cancer worldwide. They are targeted antibodies and checkpoint inhibitors. Furthermore, growing R&D on combination therapy is increasing the immunotherapy segment. For instance, In August 2018, United States Food and Drug Administration approved a combination of immunotherapeutic drugs ipilimumab (Yervoy), and nivolumab (Opdivo) to treat metastatic colorectal cancer have been treated previously with standard chemotherapy drugs. Moreover, the expansion of therapeutic applications of immunotherapeutic agents to colorectal cancer further increases the market growth.

Based on Distribution channel, the hospital pharmacy are expected to dominate the Global Colorectal Cancer Drugs market during the forecast period

The hospital pharmacies held the largest share in the global colorectal cancer drugs market. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.Also the medications can only be administrated by intravenously under supervision of medical practioners at these locations.

Geographical Analysis

North America served the largest share of the market due to the increasing prevalence of urological cancer diseases. According to the American Cancer Society's estimates for the number of colorectal cancer cases in the United States for 2021 are: 104,270 new cases of colon cancer, 45,230 new cases of rectal cancer. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel chemotherapy and immunotherapy methods, the total availability of advanced technological tools, FDA approval of new drugs and many companies are developing oncology products.

The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, Chi-Med's Fruquintinob has got approved for the treatment of colorectal cancer in China. This is expected to increase access to colorectal cancer therapeutics in China.

Competitive Landscape

The Global Colorectal Cancer Drugs Market is quite competitive with some key competitors like Genentech, Pfizer, Roche, Sanofi, Bristol-Myers Squibb, Amgen, Merck & Co, Teva Pharmaceuticals, Eli Lilly and Company, Abbott Laboratories. The key players are adopting various growth strategies such as product launch, acquisitions and investments in multiple sectors. For instance, In July 2019 - Pfizer, a key player in the market for colorectal cancer medications, completed the acquisition of Array BioPharma Inc. for strengthening the oncology pipeline for colorectal cancer treatment.

Roche Inc.

Roche was founded in 1896 in Basel, Switzerland. It creates innovative medicines and diagnostic tests that help millions of patients globally. Roche was one of the first companies to bring targeted treatments to patients. With our combined strength in pharmaceuticals and diagnostics, we are better equipped than any other company to drive personalized healthcare further. Two-thirds of our Research and Development projects are being developed with companion diagnostics.

Product Portfolio: The company portfolio includes Oncology, Neurology, Endocrinology, Infectious diseases and others.

Key developments:

• Disease - Colorectal Cancer
• Treatment - Drug: Bevacizumab, Drug: Capecitabine
• Phase - Phase 3
• Sponsor - Hoffmann-La Roche

Why Purchase the Report?

• Visualize the composition of the global Colorectal Cancer Drugs market segmentation by Type, by Therapy, by Distribution channel and region highlighting the key commercial assets and players.

• Identify commercial opportunities in Colorectal Cancer Drugs market by analyzing trends and co-development deals.

• Excel data sheet with thousands of data points of Colorectal Cancer Drugs market- level 4/5 segmentation.

• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

• Product mapping in excel for the key product of all major market players

The global calcium channel blocker report would provide an access to an approx. market data 61 tables, 56 figures and 240 pages.

Target Audience

• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
• Manufacturers

Table of Contents

1. Global Colorectal Cancer Drugs Market Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Global Colorectal Cancer Drugs Market - Market Definition and Overview

3. Global Colorectal Cancer Drugs Market - Executive Summary

• 3.1. Market Snippet by Type
• 3.2. Market snippet by Therapy
• 3.3. Market Snippet by Distribution Channel
• 3.4. Market Snippet by Region

4. Global Colorectal cancer drugs Market - Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing incidence of Colorectal cancer diseases
    • 4.1.1.2. Increased Awareness and Effective Product Launches
  • 4.1.2. Restraints:
    • 4.1.2.1. Increased usage of biologicals and targeted therapies
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Global Colorectal cancer drugs Market - Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Reimbursement Analysis
• 5.6. Unmet Needs

6. Global Colorectal cancer drugs Market - COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. Global Colorectal cancer drugs Market - By Type

• 7.1. Introduction
• 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
• 7.3. Market Attractiveness Index, By Type Segment
  • 7.3.1.1. Vascular endothelial growth factor inhibitors (VEGF)*
  • 7.3.1.2. Introduction
  • 7.3.1.3. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 7.3.2. Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
  • 7.3.3. Tyrosine Kinase (TKI) Inhibitors
  • 7.3.4. Immunomodulators
  • 7.3.5. BRAF or MEK Inhibitors

8. Global Colorectal cancer drugs Market - By Therapy

• 8.1. Introduction
• 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
• 8.3. Market Attractiveness Index, By Therapy
  • 8.3.1. Immunotherapy *
    • 8.3.1.1. Introduction
    • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 8.3.2. Targeted therapy
  • 8.3.3. Chemotherapy

9. Global Colorectal cancer drugs Market - By Distribution channels

• 9.1. Introduction
• 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channels
• 9.3. Market Attractiveness Index, By Distribution channels
  • 9.3.1. Hospital Pharmacies*
    • 9.3.1.1. Introduction
    • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 9.3.2. Retail Pharmacies
  • 9.3.3. Online Pharmacies
  • 9.3.4. Others

10. Global Colorectal cancer drugs Market - By Region

• 10.1. Introduction
• 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
• 10.3. Market Attractiveness Index, By Region
• 10.4. North America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. U.S.
    • 10.4.6.2. Canada
    • 10.4.6.3. Mexico
• 10.5. Europe
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. Germany
    • 10.5.6.2. U.K.
    • 10.5.6.3. France
    • 10.5.6.4. Italy
    • 10.5.6.5. Spain
    • 10.5.6.6. Rest of Europe
• 10.6. South America
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
  • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.6.6.1. Brazil
    • 10.6.6.2. Argentina
    • 10.6.6.3. Rest of South America
• 10.7. Asia Pacific
  • 10.7.1. Introduction
  • 10.7.2. Key Region-Specific Dynamics
  • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
  • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
  • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.7.6.1. China
    • 10.7.6.2. India
    • 10.7.6.3. Japan
    • 10.7.6.4. Australia
    • 10.7.6.5. Rest of Asia Pacific
• 10.8. Middle East and Africa
  • 10.8.1. Introduction
  • 10.8.2. Key Region-Specific Dynamics
  • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
  • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
  • 10.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11. Global Colorectal cancer drugs Market - Company Profiles

• 11.1. Roche*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Key Highlights
  • 11.1.4. Financial Overview
• 11.2. Eli Lilly and Company.,
• 11.3. Pfizer.,
• 11.4. Abbott Laboratories.,
• 11.5. Sanofi S.A.,
• 11.6. Bristol-Myers Squibb.,
• 11.7. Amgen.,
• 11.8. Genentech.,
• 11.9. Merck & Co.,
• 11.10. Teva Pharmaceuticals.

LIST NOT EXHAUSTIVE

12. Global Colorectal cancer drugs Market - DataM

• 12.1. Appendix
• 12.2. About Us and Services
• 12.3. Contact Us